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Abstract
According to the Pan American Health Organization (PAHO) reports, the annual average
number of dengue cases in the Americas has been 1,579,658 in the last 8 years (2010–2017),
affecting the population’s welfare. The high level in dengue cases does not only have an
impact from an epidemiological perspective but also from an economical perspective as
the treatment cost that must be borne. The aim of this chapter is to review the situation as
reported in the American countries with the highest number of cases, focusing on the
burden of the disease (measured in DALYs and number of cases) and its total treatment
cost, which includes direct (medical and non-medical) costs and indirect costs. We calcu-
late the total treatment cost per DALY for the epidemic year (2015). The results show that
Mexico has the highest cost per DALY (US$ 17,703) followed by Brazil (US$ 11,218),
Colombia (US$ 4,540), and the Dominican Republic (US$ 1,157). Additionally, after
adjusting for total health expenditure, we found all the countries exhibit a similar share
of total treatment cost over health expenditure (0.16% in average).
Keywords: dengue, disease outbreaks, epidemiologic measurements, disability adjusted
life year, economics costs
1. Introduction
Dengue is a viral infection endemic to tropical regions, which is transmitted by Aedes aegypti
and Aedes albopictus mosquitoes. It usually presents a cyclic behavior with peaks separated by
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
3–5 years [1–3]. Even though this illness has been present for many years in tropical countries,
the main prevention strategy is controlling the vector that carries the infection. Nowadays,
vector control and prevention programs are the only strategies in the hands of public officials
to handle and reduce dengue incidence.
In the 1970s, because of the vector control campaign against yellow fever, dengue was close to
be eliminated, but then it showed a reinvasion that has been present to this day [4]. The
constant presence of the illness (and the mosquitoes) is related with the suboptimal conditions
of trash collection, piped water supplies and uncontrolled urban development [5]. Another
possible cause is climate change [6]. Warming temperatures have expanded the endemic
territories of the A. aegypti and A. albopictus mosquitoes allowing them to be present in larger
areas [7], which added to the low efficacy of vector control strategies and create the perfect
scenario for the number of dengue cases to rise. Unfortunately, the programs aimed to control
the mosquito population have low success rates which are reflected in the consistent high
number of dengue cases in the last decade.
In recent years, there has been enough interest from the pharmaceutical industry to develop a
dengue vaccine that could act as a preventive strategy against the infection [8–10]. Neverthe-
less, most dengue vaccine strategies are still in their final stages before implementation [11].
Figure 1 shows the evolution of the reported dengue cases in the Americas for the period 2010–
2017, from which it can be observed a drastic decline in the year 2017 after 2 years of high
levels of dengue cases. Particularly, 2015 corresponds to the year with the highest number of
cases in the region, which suggest it was an epidemic year. Given the cyclic behavior of the
disease, the year 2017 could be interpreted as an interepidemic year.
The World Health Organization (WHO) recommends conducting an economic analysis for
infectious disease to estimate the cost borne by the society, especially in low- and middle-
income countries. These studies provide information to the governments that help them design
policies and allocate public resources that achieve a positive impact on public health. The most
common and recommended type of analysis is the cost-effectiveness analysis (CEA), which
Figure 1. Evolution of reported dengue cases in the Americas (2010–2017). Source: PAHO.
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compares different healthcare interventions estimating the economic costs and health gains
(usually measured as Disability-Adjusted Life Years) of each intervention and hence identifies
strategies with the potential of yielding the greatest health improvement for the least resources
used [12]. The aforesaid type of analysis consists of two main elements, the burden estimation
in the status quo scenario or current condition and the estimation in the intervention scenario.
From this perspective, the analysis conducted in this chapter presents the burden estimation in
the status quo scenario.
As well as Latin-American and Caribbean countries, Asian countries have also been affected
by dengue. Epidemiological studies conducted for Myanmar show that DALYs per million of
inhabitants lost ranged between 90 and 97 in the 1990s [13], while in Thailand, the burden was
estimated at 427 DALYs per million in the early 2000s. The latter allow us to have a frame of
reference about the burden of dengue. Due to the increasing number of cases in Americas and
Asia [14–16] and the economic cost that society must borne to treat (medical and out-of-pocket
costs) and control the disease (prevention and promotion, surveillance and control activities),
dengue continues to be a public health priority, especially in the regions previously mentioned.
This chapter aims to present a recent picture of the treatment costs, generated by the disease
and borne by the healthcare system and households, and its burden on the public health in
relevant countries for each one of the main territories of the Americas.
The following sections contain: the explanation of the criteria used to select the group of
countries for which the total economic cost and burden of the disease were calculated (Coun-
tries selection); the methodology used for estimating the DALY and the total economic cost, as
well as the necessary adjustment in the cost figures (Materials and methods); the main results
for the year 2015 (Results) and finally a brief discussion on the current levels of incidence of
dengue as a comparison between 2015 and 2017 in terms of total costs and burden. By
estimating the burden for 2015, which corresponds to the year with the highest number of
reported dengue cases, according to PAHO, we can estimate the impact that dengue has on
public health and health expenditure in an epidemic year. In contrast, having the results for
2017 not only shows a more recent level of the burden but also serve as a comparison of the
disease’s impact between epidemic and inter-epidemic years. It is worth noting that even
though the figures used in this chapter correspond to official figures collected by PAHO,
underreport in the information health systems is an element that could hide the real burden1.
2. Countries selection
To select the countries reviewed, we consider two main elements. The total number of dengue
cases in each country according to Pan American Health Organization (PAHO) reports and the
availability of information regarding total and average economic costs (per patient). Additionally,
1
Although it is challenging to estimate a robust level for underreport, attempts have been made. In Brazil the underreport
expansion factor for total dengue cases have been estimated in 1.6, while in Nicaragua this estimation goes as high as 28.
Additionally, the estimation for the underreport factor specific for severe dengue cases ranges from 1.4 to 3 [20].
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we aimed for having a relevant2 country for each one of the main territories of the Americas as
described by PAHO: Central America and Mexico, Andean, Southern Cone, and the Carib-
bean3 (Map 1). Given that dengue cases recorded in North America usually correspond to non-
endemic cases, we exclude from this chapter the information related to the USA and Canada.
To obtain robust figures for each country and avoid making a selection based on a particular
year, we used the aggregated figures, by adding the total number of reported cases and death
for the period 2014–2017. Based on the total number of reported dengue cases and deaths, we
Map 1. Incidence per 100,000 inhabitants in Americas (2014–2017). Source: PAHO. 2017.
2
We consider a country as relevant based on the burden of the disease in terms of reported dengue cases and dengue
related deaths.
3
As Caribbean territory we considered both Latin Caribbean and Non-Latin Caribbean.
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selected Mexico as the representative country of the Central America and Mexico territory
(Figure 2). Mexico has the highest number of dengue deaths (149) as well as the highest
number of reported dengue cases (564,498). Another benefit of reviewing the Mexican case is
the availability of information regarding total and per patient economic cost through a micro-
costing approach [17]. Similarly, for the Andean territory, we observed that the country with
the highest number of reported dengue cases (337,018) and deaths (318) is Colombia (Figure 3).
For this country, the cost for patient was calculated using a micro-costing approach that
employed the administrative records of the national healthcare system and a household survey
conducted by the authors [18].
In the Southern Cone territory (Figure 4), we observe Brazil as the country with the highest
number of dengue cases (3,992,664) and deaths (2,048). The latter is particularly expected since
Figure 2. Dengue cases and mortality in Central America and Mexico territory (2014–2017). Source: PAHO. 2017.
Figure 3. Dengue cases and mortality in Andean territory (2014–2017). Source: PAHO. 2017.
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not only Brazil has the largest population in the region (Southern Cone and Andean territory),
but also the other countries in this territory are sub-tropical (Paraguay) and non-tropical (Chile,
Argentina and Uruguay). The advantage of reviewing the Brazilian case is the large evidence of
total and per patient economics costs which has been estimated using micro-costing, bottom-
up approach from administrative records, household survey and interviews [19].
Finally, for the Caribbean territory, we found that, based on the information from PAHO,
between 2014 and 2017, the country with the highest number of dengue cases (31,326) and
deaths (209) is the Dominican Republic (Figure 5). In contrast to Brazil, Colombia and Mexico,
no published study, which quantifies the cost of the disease per patient considering the same
cost structure framework commonly found in the literature (direct and indirect costs), was
Figure 4. Dengue cases and mortality in Southern Cone territory (2014–2017). Source: PAHO. 2017.
Figure 5. Dengue cases and mortality in the Caribbean territory (2014–2017). Source: PAHO. 2017.
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found. Thus, we used the costs per patient estimated by Shepard [20] by extrapolating the
results from other countries and considering the differences in purchasing power and income4.
3. Materials and methods
To assess the economic cost of the disease, we used the results found for Brazil, Colombia, the
Dominican Republic, and Mexico. To maintain cost structure homogeneity, we exploited the
common methodological framework used in the literature, which is employed in the papers
reviewed. There are three main cost categories used to quantify the economic burden of a
disease: direct medical cost, direct non-medical cost, and indirect cost.
Direct medical cost comprises the cost borne by the healthcare unit (professional services,
medical inputs, medical drugs, laboratory test). Additionally, direct non-medical cost corre-
sponds to the value expended during a dengue episode and comprises food, lodging and travel
expenses. Finally, indirect cost includes the productivity loss5 (by patient and caregivers).
Even though the authors researched a common topic, there are some methodological differ-
ences that are worth noting to make a correct comparison between the results. In contrast to
Mexico [17], Colombia [18] and Brazil [19] estimate the direct cost per patient grouping the
medical and non-medical component in the same category, thus their figures could only be
compared to the sum of medical and non-medical direct cost6 from Mexico and Colombia.
Although the three studies present their results in dollars, nominal adjustment7 was needed8,
for this we use the GDP deflator calculated by the World Bank for each country. Once the
appropriate per patient is defined, the total number of reported dengue cases is required to
estimate the total cost in each country; for this, we took the information reported by PAHO for
4
More details about the methodology employed by the authors can be found in [20].
5
Productivity loss corresponds to a monetary estimate of the days of work lost by the patient as well as caregivers.
6
Direct non-medical costs include out-of-pocket expenses borne by the patient.
7
Nominal adjustment accounts for price changes due to inflation between years. This adjustment allows for proper
comparison between figures from different years.
8
To nominally adjust the cost figures the GDP deflator was used for two different years i; jð Þ.
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the year 20159. Considering potential lack of homogeneity among countries regarding labora-
tory confirmation practices and policies, we used total reported cases instead of laboratory
confirmed cases for our analysis; we allow for this since reported dengue cases also received
treatment and PAHO definition for reported cases only includes people “who has a fever or
history of fever for 2-7 days duration, two or more symptoms of dengue and one serological
test positive or epidemiological nexus with confirmed dengue case 14 days before onset of
symptom.” Even though using reported dengue cases, we are allowing for a potential
overestimation of the economic burden, it is worth noting that by using DALY figures from
WHO, we avoid this potential bias in the burden of the disease. It might also be noted that by
using this approach, the results we found could be interpreted as an upper bound for the
economic burden of the disease. To calculate the total treatment cost, we make the following
assumption, and severe cases are considered to receive hospitalized treatment while nonsevere
dengue cases10 are considered to receive ambulatory treatment. From now on, we will refer
only to ambulatory cases and hospitalized cases.
Total treatment cost was calculated for both ambulatory and hospitalized cases as presented in
Eq. (1).
TC ¼ AD PPCambulatory þHD PPChospitalized (1)
where TC represents total cost, AD number of ambulatory dengue cases, HD number of
hospitalized dengue cases, and PPC per patient cost.
PPCi ¼ DMCi þDnMCi þ ICi,
i∈ ambulatory; hospitalizedf g (2)
where DMC represents direct medical cost, DnMC direct non-medical cost and IMC indirect
cost. In other words, the total cost of the disease is equal to the number of dengue cases times
the cost per patient, for both ambulatory and hospitalized cases. The total treatment cost per
patient corresponds to the sum of direct medical cost per patient, direct non-medical cost per
patient and indirect cost per patient.
As estimates for the burden of the disease, measured as the number of Disability Adjusted Life
Years (DALY)11, we use the figures from the World Health Organization (WHO) for the year
9
We considered the last published report that includes the information from the whole year. PAHO gathers epidemiolog-
ical information from official reports made by the countries themselves. Thus, PAHO figures represent the official number
of reported dengue cases, death and incidence. This mechanism has been working since 1980 and nowadays counts with
systems of mandatory notification across the national territories.
10
The number of ambulatory dengue cases is equal to the total number of reported cases minus the total number of
hospitalized cases; both figures are used as reported by PAHO.
11
According to WHO, one Disability Adjusted Life Years can be thought of as one lost year of “healthy” life. The sum of
these DALYs across the population can be thought of as a measurement of the gap between current health status and an
ideal health situation where the entire population lives to an advanced age, free of disease and disability and are
calculated as the sum of the Years of Life Lost (YLL) due to premature mortality in the population and the Years Lost
due to Disability (YLD) for people living with the health condition or its consequence.
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2015; we preferred DALYs as measurement of the disease’s burden because it allows to express
numerically the burden of the disease as years based on a set of standard weights [21].
Additionally, to estimate the number of DALYs for 2017, which is presented in the discussion
section, we used the following approach. Using the DALY estimates of WHO for 2015 and the
number of cases of dengue reported by PAHO, we calculated the ratio of DALY per reported





DALY2017 ¼ rDALY  #Cases2017PAHO (4)
This approach relies on one underlying assumptions, mortality rates do not change dramati-
cally from 2015 to 201712. It is noteworthy that following this approach, we benefit from the
WHO information about DALY estimation parameters, reduce bias (noise) from lack of spe-
cific data needed to estimate the burden of the disease13 and get highly comparable estima-
tions from a homogeneous methodology.
4. Results
After nominally adjusting the figures, the cost per patient found by the authors for Brazil,
Colombia, the Dominican Republic, and Mexico are shown in Table 1. Since the authors used
the same cost structure in their estimation process, we can separate the total cost into their
main categories (direct medical and non-medical cost and indirect cost). The figures are
presented in 2017 prices, which allows for comparison. Table 1 shows the total cost per patient
disaggregated.
In the four countries reviewed, Mexico is the one with the most expensive treatment cost per
patient in ambulatory care, even when their indirect cost is the lowest. For ambulatory cases, in
contrast to Brazil, Colombia, and the Dominican Republic, the direct medical cost in Mexico is
larger than the direct non-medical cost and the indirect cost (even when combined). For
hospitalized cases, Mexico keeps having the most expensive treatment cost per patient, with
direct costs that more than double the direct costs of the other countries.
The latter shows that Mexico has the most expensive dengue treatment per patient, regardless
of the type of care (ambulatory US$ 501 or hospitalized US$ 1,475). On the other hand, the less
expensive treatment for ambulatory (US$ 189) and hospitalized (US$ 488) cases would be
in Brazil.
12
We do not find this assumption to be particularly strong.
13
Recalling the method used to estimate the total cost of the disease it is noteworthy that the latent risk of overestimation is
not present in the estimation of the burden of the disease (DALY), as it is estimated by extrapolating the results of 2005
using the ratio of DALY per reported dengue case.
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Since the number of cases presented in Table 2 is not corrected by country-specific population,
they cannot be directly compared between themselves; nevertheless, we can observe that more
than half the total number of de dengue cases in the Americas in 2015 are located in Brazil
(69.1%) and although the population of Brazil is less than twice the population of Mexico, its
number of dengue cases exceeds twice the number dengue cases of the latter. This exhibits a
concerning situation for the public health in Brazil. Once we controlled for the population of
each country, we found that in 2015, the lowest incidence rate corresponds to the Dominican
Republic and the highest to Brazil. Although the Dominican Republic has the lowest incidence
rate, its mortality rate is much higher than that of the other countries.
Once we have defined the total number of dengue cases for each country and its corresponding
treatment cost, it is possible to calculate the total cost following Eqs. (1) and (2). Table 3
exhibits the total treatment cost for the year 2015 (in 2017 prices). In absolute terms, the highest
economic cost corresponds to Brazil, which, as was shown before, has the less expensive
treatment cost per patient, hence the extent of the total cost is mainly due to the high incidence
Brazil Colombia The Dominican Republic Mexico
Cost per ambulatory patient
Direct medical $70 $75 $75 $281
Direct non-medical $33 $14 $102
Indirect $119 $219 $136 $118
Total $189 $327 $224 $501
Cost per hospitalized patient
Direct medical $258 $368 $366 $1,123
Direct non-medical $59 $152 $193
Indirect $230 $345 $366 $159
Total $488 $771 $883 $1,475
Source: Martelli, et al. (2015) [19], Castro, et al. (2015) [18], Undurraga, et al. (2014) [17], Shepard, et al. (2011) [20]. Prices
2017.
Table 1. Treatment cost per patient by country (nominally adjusted 2017 dollars).
Brazil Colombia The Dominican Republic Mexico
Number of cases
Ambulatory dengue 1,647,439 95,023 15,194 214,129
Hospitalized dengue 1,569 1,421 1,854 5,464
Deaths 863 155 107 42
Incidence per 10.000 inhabitants 80.6 20.0 17.1 18.1
Mortality rate (%) 0.05 0.16 0.63 0.02
Source: PAHO. 2015. Week 52. IMF.
Table 2. Number of cases, death and epidemiological by country (2015).
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in the country. In terms of burden of the disease, measured as DALY, Brazil keep having the
highest figures in absolute terms (49,500 DALYS), followed by Colombia (16,200 DALYS).
Having DALY in absolute terms does not allow for a proper comparison, therefore, we adjusted
the results by dividing them by the country-specific population. Hence, we could express the
burden of the disease as the number of DALY per million inhabitants, which is now perfectly
comparable between countries. Now, Brazil is not the country with the highest burden relative to
its population size, but the Dominican Republic (336 DALYS per million inhabitants), followed
by Colombia, which remains in second place (962 DALYS per million inhabitants).
As well as adjusting the DALY by the population, it is also important to adjust the total
treatment cost relative to some economic measure that allows to compare figures between
countries in a proper manner. One alternative is to present the results as share of the total
Gross Domestic Product (GDP) of each country, but this approach has two disadvantages.
First, the resulting figures are too small, which by multiplying them by a factor makes the
interpretation more difficult, and second, it does not consider GDP composition. Instead, we
have used the total health expenditure estimated by the World Bank (WB) to adjust the total
treatment cost. Table 4 exhibits the total health expenditure by country in US billion dollars for
2015 (in 2017 prices).
Once adjusted, the total annual cost is very similar among countries. Notably, Colombia and
Mexico spend nearly the same proportion (0.18%) of their health expenditure in dengue
treatment, and Brazil has a lower share than the latter (0.16%). Given the country selection
criteria used, one could assert that the average share of total cost caused by dengue treatment
Brazil Colombia The Dominican Republic Mexico
Total ambulatory (US Dollars) 310,672,689 31,052,056 3,411,045 107,351,329
Total hospitalized (US Dollars) 766,211 1,096,202 1,637,140 8,060,036
Total cost (US Dollars) 311,438,900 32,148,258 5,048,184 115,411,366
Total DALY 49,500 16,200 9,600 12,100
Population 204,469,667 48,202,951 9,980,185 121,006,250
DALY per million inhabitants 242 336 962 100
Source: PAHO. 2015. Week 52. Martelli, et al. (2015) [19], Castro, et al. (2015) [18], Undurraga, et al. (2014) [17], Shepard,
et al. (2011) [20]. Prices 2017.
Table 3. Total annual treatment cost and DALYs lost per million inhabitants by country (2015). 2017 dollars.
Brazil Colombia The Dominican Republic Mexico
GDP (US Dollars billions) 2,142 297 67 1,093
Health expenditure (US Dollars billions) 191 18 4 64
Health expenditure (% of GDP) 8.9 6.2 6.2 5.9
Source: World Bank. IMF.
Table 4. Total health expenditure (2015). 2017 dollars.
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in health expenditure in an epidemic year is 0.16% for the countries with the highest number of
cases (Table 5). Although this result cannot be perfectly extrapolated to all the countries of the
Americas, it could be interpreted as an upper bound for the size of the economic burden of
dengue in the region.
Figure 6 shows the normalized treatment cost14 and burden for each country. We can observe
that while the Dominican Republic is the country with the highest number of DALY adjusted by
population, it has the lowest cost per each DALY lost because of the disease. In contrast, Mexico
has the highest cost per DALY lost, but the lowest number of DALY adjusted by population.
Finally, Table 6 exhibits the 2015 total economic cost per DALY adjusted for purchasing power
parity (PPP). There appears to be high variance in the total treatment cost, with its ranges from
$1,157 in the case of the Dominican Republic to $17,703 for Mexico. It is noteworthy that
Mexico, in relative terms, always presents the highest treatment cost. This result is consistent
whether we analyze the total treatment cost per patient, the share of total annual cost over the
total health expenditure or the total treatment per DALY adjusted for PPP.
Figure 6. Normalized results. 2015. Source: PAHO. 2015. Week 52. Martelli, et al. (2015) [19], Castro, et al. (2015) [18],
Undurraga, et al. (2014) [17], Shepard, et al. (2011) [20]. Prices 2017.
Brazil Colombia The Dominican Republic Mexico
Total ambulatory (%) 0.16 0.17 0.08 0.17
Total hospitalized (%) 0.00 0.01 0.04 0.01
Total cost (%) 0.16 0.18 0.12 0.18
Source: PAHO. 2015. Week 52. Martelli, et al. (2015) [19], Castro, et al. (2015) [18], Undurraga, et al. (2014) [17], Shepard,
et al. (2011) [20]. Prices 2017.
Table 5. Total annual treatment cost as share of the total health expenditure (2015).
14
Variable definition: level of current health expenditure expressed as a percentage of GDP. Estimates of current health
expenditures include healthcare goods and services consumed during each year. This indicator does not include capital
health expenditures such as buildings, machinery, innovation and technology and stocks of vaccines for emergency or
outbreaks.
Dengue Fever - a Resilient Threat in the Face of Innovation32
The variance in the results could be explained by the income gap between countries. If we
consider the GDP per capital as proxy for the median income of each country, it makes sense
that Mexico and Brazil have the highest cost per case and DALY since their GDP (US$ 9,033
and US$ 10,476 respectively) is close to 50% higher than the GDP per capita of Colombia and
the Dominican Republic (US$ 6,161 and US$ 6,713 respectively).
5. Discussion
According to the review made by Shepard [22], who estimate the burden at a global scale for
the year 2013, Latin-American and the Caribbean regions exhibit the highest treatment cost per
case. From this perspective, our review presents the burden of the disease for the most affected
countries, in terms of reported cases, of the region with the most expensive treatment cost. The
latter is particularly relevant if we considered the estimates of the share of total treatment cost
over the total health expenditure presented because our results could be interpreted as an
upper bound for relative economic burden of dengue.
As mentioned before, in this section, we will discuss how the total treatment cost and the
burden change in 2017, which we consider to be an inter-epidemic year given the low number
of cases relative to previous years (2010–2017) (Table 7).
Brazil Colombia The Dominican Republic Mexico
Total ambulatory (PPP Dollars) $11,190.5 $4,385.6 $782.0 $16,466.4
Total hospitalized (PPP Dollars) $27.6 $154.8 $375.3 $1,236.3
Total cost (PPP Dollars) $11,218.1 $4,540.4 $1,157.3 $17,702.7
Source: PAHO. 2015. Week 52. Martelli, et al. (2015) [19], Castro, et al. (2015) [18], Undurraga, et al. (2014) [17], Shepard,
et al. (2011) [20]. Prices 2017.
Table 6. 2015 Total economic cost per DALY (2017 PPP dollars).
Brazil Colombia The Dominican Republic Mexico
Total ambulatory (US Dollars) 47,458,401 8,494,113 285,339 44,878,911
Total hospitalized (US Dollars) 184,593.94 220,629 77,707 553,169
Total treatment cost (US Dollars) 47,642,995 8,714,742 363,046 45,432,079
Total DALY 7,599 2,481 259 7,554
Population 207,680,999 49,293,878 10,172,243 123,517,856
DALY per 1 million inhabitants 37 50 25 61
Source: PAHO. 2017. Week 52. Martelli, et al. (2015) [19], Castro, et al. (2015) [18], Undurraga, et al. (2014) [17], Shepard,
et al. (2011) [20]. Prices 2017.
Table 7. 2017 Economic and DALY lost per million inhabitants by country (2017 dollars).
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To estimate the total number of DALY for the year 2017, we calculated the ratio between
dengue cases and DALY for 2015 with the WHO and PAHO figures and extrapolate the results
as discussed in section “Materials and methods.” Population has been updated too, to corre-
spond to the year 2017. DALY adjusted for population present a dramatic decline of 76.53% in
average due to the decrease in total number of dengue cases. Additionally, the total treatment
cost of the disease decreased 77.8% in average (from 2015 to 2017), being Dominica Republic
the country with the highest reduction rate (92.8%). It is worth saying that the change in the
figures is closely tied to the change in the number of dengue cases since the cost per patient
remained the same (Table 8).15
As result of the decline in the number dengue cases in 2017, the share of the total costs
decreased to almost a fifth of the share in 2015 (Figure 7).
15
Cost per patient do not vary since they are expressed in 2017 dollar are correspond to the figures obtained in the
respective studies reviewed.
Figure 7. Normalized results. 2017. Source: PAHO. 2017. Week 52. Martelli, et al. (2015) [19], Castro, et al. (2015) [18],
Undurraga, et al. (2014) [17], Shepard, et al. (2011) [20]. Prices 2017.
Brazil Colombia The Dominican Republic Mexico
GDP (US Dollars billions) 2,081 307 75 1,142
Health expenditure (% of GDP) 8.9 6.2 6.2 5.9
Health expenditure (US Dollars billions) 185 19 5 67
Total ambulatory (%) 0.03% 0.04% 0.01% 0.07%
Total hospitalized (%) 0.00% 0.00% 0.00% 0.00%
Total cost (%) 0.03% 0.05% 0.01% 0.07%
Source: PAHO. 2017. Week 52. Martelli, et al. (2015) [19], Castro, et al. (2015) [18], Undurraga, et al. (2014) [17], Shepard,
et al. (2011) [20]. Prices 2017.
Table 8. Total health expenditure and 2017 total economic cost as share of the total health expenditure (2017 dollars).
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Normalized results for 2017 show that, in contrast to 2015, the Dominican Republic exhibits
both the lowest total treatment cost per DALY and DALY per million of inhabitants, which
suggest an improvement for the Caribbean country, especially considering the noneconomic
burden. On the other hand, Mexico went from having the lowest number of DALY adjusted
for population to having one of the highest.
One important limitation about this review and potentially other burden analyses is the
accuracy of the epidemiological information. As the number of total dengue cases, severe and
non-severe, corresponds to reported cases, one cannot assume that they correspond to the
effective number of cases. Reported (or febrile) cases can overestimate the total actual burden
of the disease. On the other hand, one should consider that by using laboratory confirmed
cases, bias in the other direction is introduced, since not only that figure would be affected by
laboratory confirmation policies and practices but also by underreport. After reviewing the
latter, we decided to use reported cases and allow for potential overestimation in the economic
burden. Thus, our results should be considered as upper bound estimates of the economic
burden16 and not completely accurate figures.
The results found have three interesting implications for further studies and reviews. Economic
burden of dengue should follow a structured costing framing, which allows for proper com-
parison between results and better estimation of treatment cost per case. The data and sources
used in this chapter could serve as inputs in future cost-effectiveness analysis (CEA); once
economic cost per cases has been covered, the remaining element to conduct a CEA would be
the approximate reduction in dengue cases due to the use of a prevention technology. Finally, the
similar results in terms of relative economic burden suggest that 0.16%17 could be interpreted
as an upper bound of the total treatment cost of dengue as share of total health expenditure.
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